trial · primary record
Trastuzumab Rezetecan (SHR-A1811)
Gastric Adenocarcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 62 |
| Primary completion | 2029-10-31 |
| Primary endpoint | Pathological complete response (pCR) rate |
| Registry ID | NCT07912957 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:59:24.663Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07912957
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.